Comment on ‘Management of Cardiac Sarcoidosis in 2020’

Register or Login to View PDF Permissions
Permissions× For commercial reprint enquiries please contact Springer Healthcare:

For permissions and non-commercial reprint enquiries, please visit to start a request.

For author reprints, please email
Information image
Average (ratings)
No ratings
Your rating

Disclosure:The authors have no conflicts of interest to declare.



Published online:

Correspondence Details:Socrates Korovesis, Department of Cardiology, Hygeia Hospital, 15123 Athens, Greece. E:

Open Access:

This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.

We read with great interest the profound and instructive review by Gilotra et al. on cardiac sarcoidosis.1 However, we were surprised to see no comment on the raised possibility that steroids might precipitate electrical instability.2 Ventricular tachyarrhythmias and electric storm have been reported to frequently occur in the first 12 months after initiation of corticosteroid therapy.3 This is an issue of clinical importance and it would have been useful to include this in the review along with a commentary from the authors.


  1. Gilotra N, Okada D, Sharma A, Chrispin J. Management of cardiac sarcoidosis in 2020. Arryth Electrophysiol Rev 2020;9:182–8.
    Crossref | PubMed
  2. Okada DR, Smith J, Derakhshan A, et al. Ventricular arrhythmias in cardiac sarcoidosis. Circulation 2018;138:1253–64.
    Crossref | PubMed
  3. Segawa M, Fukuda K, Nakano M, et al. Time course and factors correlating with ventricular tachyarrhythmias after introduction of steroid therapy in cardiac sarcoidosis. Circ Arrhythm Electrophysiol 2016;9:e003353.
    Crossref | PubMed